Progesterone pharmaceutical composition

The invention provides a progesterone pharmaceutical composition. Specifically, provided is an oral formulation comprising (a) progesterone; (b) a progesterone biological utilization accelerant; and (c) and a pharmaceutically acceptable oral formulation carrier. Wherein the progesterone biological utilization accelerant is selected from one or more of sucrose fatty acid esters. The oral preparation disclosed by the invention is high in bioavailability and low in side effect, and is a better progesterone oral product. 本发明提供了一种黄体酮药物组合物。具体地，提供了一种口服制剂，包括(a)黄体酮；(b)黄体酮生物利用促进剂；和(c)以及药学上可接受的口服制剂载体。其中，所述黄体酮生物利用促进剂选自蔗糖脂肪酸酯中的一种或多种。本发明的口服制剂生物利用度高、副作用低，是一种更优的黄体酮口服产品。